Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer

Emma H Allott, Elizabeth M Masko, Alexis R Freedland, Everardo Macias, Kristine Pelton, Keith R Solomon, Elahe A Mostaghel, George V Thomas, Salvatore V Pizzo, Michael R Freeman, Stephen J Freedland

Research output: Contribution to journalArticle

8 Citations (Scopus)
188 Downloads (Pure)

Abstract

BACKGROUND: Some, but not all, epidemiologic evidence supports a role for cholesterol, the precursor for steroid hormone synthesis, in prostate cancer. Using a PTEN-null transgenic mouse model of prostate cancer, we tested the effect of modifying serum cholesterol levels on prostate tumor development and growth. We hypothesized that serum cholesterol reduction would lower tumor androgens and slow prostate cancer growth.

METHODS: PTENloxP/loxP-Cre+ mice consuming ad libitum high fat, high cholesterol diets (40% fat, 1.25% cholesterol) were randomized after weaning to receive the cholesterol uptake inhibitor, ezetimibe (30 mg/kg/day), or no intervention, and sacrificed at 2, 3, or 4 months of age. Serum cholesterol and testosterone were measured by ELISA and intraprostatic androgens by mass spectrometry. Prostate histology was graded, and proliferation and apoptosis in tumor epithelium and stroma was assessed by Ki67 and TUNEL, respectively.

RESULTS: Ezetimibe-treated mice had lower serum cholesterol at 4 months (p = 0.031). Serum cholesterol was positively correlated with prostate weight (p = 0.033) and tumor epithelial proliferation (p = 0.069), and negatively correlated with tumor epithelial apoptosis (p = 0.004). Serum cholesterol was unrelated to body weight (p = 0.195). Tumor stromal cell proliferation was reduced in the ezetimibe group (p = 0.010). Increased serum cholesterol at 4 months was associated with elevated intraprostatic DHEA, testosterone, and androstenedione (p = 0.043, p = 0.074, p = 0.031, respectively). However, cholesterol reduction did not significantly affect adenocarcinoma development at 2, 3, or 4 months of age (0, 78, and 100% in ezetimibe-treated vs. 0, 80, and 100% in mice not receiving ezetimibe).

CONCLUSIONS: Though serum cholesterol reduction did not significantly affect the rate of adenocarcinoma development in the PTEN-null transgenic mouse model of prostate cancer, it lowered intraprostatic androgens and slowed tumor growth. These findings support a role for serum cholesterol in promoting prostate cancer growth, potentially via enhanced tumor androgen signaling, and may provide new insight into cholesterol-lowering interventions for prostate cancer treatment.

Original languageEnglish
Pages (from-to)196-203
Number of pages8
JournalProstate cancer and prostatic diseases
Volume21
Issue number2
DOIs
Publication statusPublished - 23 May 2018

Fingerprint Dive into the research topics of 'Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Allott, E. H., Masko, E. M., Freedland, A. R., Macias, E., Pelton, K., Solomon, K. R., Mostaghel, E. A., Thomas, G. V., Pizzo, S. V., Freeman, M. R., & Freedland, S. J. (2018). Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer. Prostate cancer and prostatic diseases, 21(2), 196-203. https://doi.org/10.1038/s41391-018-0045-x